The rare and orphan disease market exhibits a number of unique characteristics that make goal setting incredibly challenging. In this blog post, we explore one proven goal setting methodology with a track record of improving goal accuracy and equity for rare disease products.

While sales compensation design for any product launch can be incredibly challenging, it is especially complex for products that treat rare and orphan diseases. In this blog post, we explore three sales compensation pitfalls to avoid for the launch of a rare disease product.

The two most common sales compensation plan periods adopted in biopharma—quarter and trimester—each have their own set of advantages and disadvantages as well as circumstances for use. In this blog post, we explore the pros and cons of these two plan period types.

Let’s investigate the limitations of the most common way to score MBOs as well as two innovative scoring strategies that drive superior accountability and performance.

With one-size-fits-all solutions often proving inadequate for solutions of minor consequence, such as shower caps, imagine how detrimental they can be when it comes to life sciences sales compensation design.